410.35
Natera Inc Borsa (NTRA) Ultime notizie
After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance Australia
Natera, Inc. (NTRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Natera stock hits all-time high at 422.19 USD - Investing.com
$1000 Invested In Natera 5 Years Ago Would Be Worth This Much Today - Benzinga
Hewlett Packard, Natera, UnitedHealth Group: CNBC ‘Final Trades’UnitedHealth Group (NYSE:UNH) - Benzinga
Form 4 Natera Inc For: 27 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September - Investing.com India
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Natera(NTRA.US) Director Sells US$7.01 Million in Common Stock - Moomoo
RBC Capital raises Natera stock price target on MRD testing growth By Investing.com - Investing.com South Africa
Final Trades: Hewlett Packard, Natera and UnitedHealth - CNBC
Natera options flow shows 12.6:1 put/call ratio near 52-week high - Investing.com
NTRA Maintained by RBC Capital -- Price Target Raised to $460 - GuruFocus
RBC Capital raises Natera stock price target on MRD testing growth - Investing.com
Natera Is Maintained at Outperform by RBC Capital - moomoo.com
RBC Capital maintains Outperform rating on Natera, $460 price target - TradingView
Natera’s Critical Pivot to Oncology - Nanalyze
RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating - marketscreener.com
Natera Inc (NTRA) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus
Svetlana Nikic Celebrates Natera’s Signatera Milestone in Japan - Oncodaily
Natera stock gains 2.75 percent after Japan test approval - AD HOC NEWS
Has Natera (NTRA) Run Ahead Of Fair Value After Its Japan Signatera Approval? - simplywall.st
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar - Yahoo Finance
Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval - insideprecisionmedicine.com
Form 144 Natera For: 23 September By Investing.com - Investing.com Canada
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Yahoo Finance
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera, Inc.Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - marketscreener.com
Why Is Natera (NTRA) Stock Soaring Today - Yahoo Finance
A Look at Natera Inc (NTRA) After 5.5% Gain -- GF Value $219.69 vs Price $390.90 - GuruFocus
Behavioral Patterns of NTRA and Institutional Flows - Stock Traders Daily
Natera Inc stock reaches all-time high at 373.58 USD By Investing.com - Investing.com Nigeria
Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement - TradingKey
Natera gains as fresh Signatera lung cancer data and upbeat analyst sentiment support shares - Quiver Quantitative
NTRA Looks 68.7% Overvalued on GF Value™ - gurufocus.com
Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer - Finviz
Natera’s Signatera Receives Japanese Approval as CDx for Muscle-Invasive Bladder Cancer - GenomeWeb
Natera Inc stock reaches all-time high at 373.58 USD - Investing.com
Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027 - TradingView
Uber, Micron, Datadog And A Health Care Stock: CNBC’s ‘Final Trades’ - Benzinga
A cancer test receives its second Japan approval in three months to guide bladder-cancer treatment. - Stock Titan
Enterprise value to EBITDA ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA.CI - TradingView
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):